Related Experiment Video
Updated: May 16, 2026
08:43
Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts
Published on: August 26, 2021
Electrical neuromodulation for patients with cardiac diseases
K De Decker1, U Beese, M J Staal
1University Medical Centre of Groningen and University of Groningen, 9700 RB, Groningen, the Netherlands.
Summary
Electrical neuromodulation offers a safe, reversible therapy for chronic cardiac conditions refractory to standard treatments. This approach effectively reduces angina, improves exercise capacity, and enhances quality of life in patients with refractory angina.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Chronic cardiac diseases, including refractory angina, heart failure, and arrhythmias, pose significant challenges when conventional treatments fail.
- Patients with refractory angina often experience debilitating symptoms and reduced quality of life despite standard medical interventions.
Purpose of the Study:
- To review the role of electrical neuromodulation as an adjuvant therapy for patients with chronic cardiac diseases refractory to conventional strategies.
- To evaluate the efficacy and safety of electrical neuromodulation in managing symptoms and improving outcomes in these patient populations.
Main Methods:
- Systematic review of existing literature on electrical neuromodulation for cardiac conditions.
- Analysis of studies investigating various electrical neuromodulation modalities and their impact on patient-reported outcomes and objective measures.
Main Results:
- Electrical neuromodulation, regardless of modality, significantly reduces angina complaints in patients with chronic refractory angina.
- This therapy enhances exercise capacity and improves the quality of life for individuals with refractory angina.
- Electrical neuromodulation demonstrates anti-ischaemic effects, positioning it as a valuable adjuvant treatment.
Conclusions:
- Electrical neuromodulation is a safe and reversible adjuvant therapy for chronic cardiac diseases refractory to conventional treatments.
- It represents a promising therapeutic option for improving symptoms and functional capacity in patients with refractory angina.
- Ongoing research is exploring neuromodulation's potential in treating heart failure and resistant arrhythmias.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:19Electrophysiology of Normal Cardiac Rhythm
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...